Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), has announced the completion of enrollment in its Phase 3 pivotal study, APPROACH, evaluating HLP003 for the adjunctive treatment of major depressive disorder. The company anticipates topline data from this trial in the fourth quarter of 2026, marking a significant milestone in its efforts to address the substantial unmet need in mental health care.
The APPROACH study is part of the broader PARADIGM program, which also includes the EMBRACE trial, where enrollment is currently underway, and the EXTEND study, which continues to roll over participants from earlier phases. This comprehensive program underscores the company's commitment to rigorously evaluating HLP003's efficacy and safety profile. HLP003 has already received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to offer meaningful improvements over existing treatments.
In addition to the progress in the depression program, Helus Pharma is advancing HLP004 for generalized anxiety disorder. Following Phase 2 results that demonstrated a statistically significant and clinically meaningful improvement from baseline, the company expects to finalize the design for the next study by the end of the third quarter. This continued momentum across its pipeline reflects the company's strategic focus on developing novel therapies that target serotonin pathways to promote neuroplasticity, potentially offering durable benefits for patients suffering from depression and anxiety.
Financially, Helus Pharma reported cash and cash equivalents of $166.4 million as of June 30, 2026. The company posted a net loss of $47.8 million for the quarter, compared to $24.6 million in the same period last year. Cash-based operating expenses rose to $37.5 million from $23.9 million, driven by the expanded clinical activities in the APPROACH, EMBRACE, and EXTEND trials. These investments are critical as the company navigates the late-stage development process and prepares for potential regulatory submissions.
Looking ahead, Helus Pharma is also making strides in its earlier-stage pipeline, with HLP005 advancing toward candidate selection. The company anticipates identifying a viable development candidate in the second half of 2027. This forward-looking approach aims to build a robust portfolio of NSAs that could transform the mental health treatment landscape.
The completion of enrollment in APPROACH is a pivotal step for Helus Pharma, as it brings the company closer to potentially delivering a new therapeutic option for the millions of individuals affected by major depressive disorder. The topline data expected in Q4 2026 will be a critical determinant of the program's future and could have significant implications for the company's valuation and the broader psychiatric treatment community.
For more detailed information on the company's financial results and pipeline developments, interested parties can refer to the full press release at https://ibn.fm/yfpOW.
